ojrdrtОнкологический журнал: лучевая диагностика, лучевая терапияJournal of oncology: diagnostic radiology and radiotherapy2587-75932713-167XНЕКОММЕРЧЕСКОЕ ПАРТНЕРСТВО «ОБЩЕСТВО ИНТЕРВЕНЦИОННЫХ ОНКОРАДИОЛОГОВ»10.37174/2587-7593-2024-7-2-63-75ojrdrt-358Research ArticleИНТЕРВЕНЦИОННАЯ РАДИОЛОГИЯINTERVENTIONAL RADIOLOGYСтандарты проведения процедуры трансартериальной химиоэмболизации при лечении пациентов с гепатоцеллюлярной карциномой: обзор литературы. Часть 1Standards for the Transarterial Chemoembolization Procedure as the Hepatocellular Carcinoma Treatment: Literature Review. Part 1https://orcid.org/0000-0002-4587-4153ПогребняковИ. В.PogrebnyakovI. V.

Погребняков Игорь Владимирович — к.м.н., заведующий отделением-врач по рентгенэндоваскулярным диагностике и лечению отделения рентгенохирургических методов диагностики и лечения отдела интервенционной радиологии НИИ КиЭР, НМИЦ онкологии им. Н.Н. Блохина Минздрава России.

115478 Москва, Каширское шоссе, 24

AuthorID 965034

Igor V. Pogrebnyakov.

24 Kashirskoye Shosse, Moscow, 115478

i.pogr@mail.ruНациональный медицинский исследовательский центр онкологии им. Н.Н. Блохина Минздрава РоссииРоссияN.N. Blokhin National Medical Research Center of OncologyRussian Federation202404072024726375Copyright © Погребняков И.В., 20242024Погребняков И.В.Pogrebnyakov I.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.oncoradjournal.ru/jour/article/view/358

В обзоре описаны современные стандарты проведения процедуры трансартериальной химиоэмболизации (ТАХЭ) у па­циентов с гепатоцеллюлярной карциномой (ГЦК). Описаны методы медицинской визуализации у больных c ГЦК перед планированием ТАХЭ, обоснованы необходимость морфологической верификации диагноза, критерии отбора пациентов для проведения рентгенэндоваскулярного лечения с учётом всех показаний и противопоказаний и квалифицированного мнения мультидисплинарного консилиума. Отображены особенности предоперационной подготовки, интрапроцедурной визуализации и описаны методики ТАХЭ, применяемые при ГЦК.

The review describes the modern classification of stages of HCC, features of radiological diagnostics, the indications for morphological verification, shows the criteria for selecting patients for endovascular treatment, and outlines all the indications and contraindications for the TACE procedure. The review shows the features of preoperative preparation, describes TACE techniques for HCC, and algorithms for their implementation.

трансартериальная химиоэмболизациягепатоцеллюлярная карциномагепатоцеллюлярный ракплоскодетекторная компьютерная томографиябиопсия печениtransarterial chemoembolizationhepatocellular carcinomacone-beam CTangiographyliver biopsyReferencesReig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681-93. https://doi.org/10.1016/j.jhep.2021.11.018Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681-93. https://doi.org/10.1016/j.jhep.2021.11.018Хайцман ДМ и др. Обзор классификаций промежуточной стадии гепатоцеллюлярной карциномы. Онкологический журнал: лучевая диагностика, лучевая терапия. 2021;4(1):53-64. https://doi.org/10.37174/2587-7593-2021-4-1-53-64.Khaitsman DM, et al. Intermediate Stage Hepatocellular Carcinoma Classifications: the Review. Journal of Ocology: Diagnostic Radiology and Radiotherapy. 2021;4(1):53-64. (In Russ.). https://doi.org/10.37174/2587-7593-2021-4-1-53-64.Долгушин БИ и др. Интервенционные радиологические технологии в лечении больных с промежуточной стадией ГЦР (BCLC B). Онкологический журнал: лучевая диагностика, лучевая терапия. 2018;1 (1):60-2. https://doi.org/10.37174/2587-7593-2018-1-1-60-62Dolgushin BI, et al. Interventional Radiological Technologies in the Treatment of Patients with an Intermediate Stage of HCC (BCLC B). Journal of Ocology: Diagnostic Radiology and Radiotherapy. 2018;1(1):60-2. (In Russ.). https://doi.org/10.37174/2587-7593-2018-1-1-60-62Виршке ЭР и др. Гепатоцеллюлярный рак, BCLC B: в поисках оптимального лечения. Интервенционные радиологические технологии в лечении больных ГЦР. Злокачественные опухоли. 2016;4-S (21):26-8.Virshke ER, et al. Hepatocellular carcinoma, BCLC B: in search of optimal treatment. Interventional Radiological Technologies in the Treatment of Patients with HCC. Malignant tumors. 2016;4-S (21):26-8. (In Russ.).Бредер ВВ и др. Гепатоцеллюлярный рак промежуточной стадии. BCLC B - официальные рекомендации, как стратегия базисного лечения и точка отсчета в оценке эффективности новых подходов. Злокачественные опухоли. 2016;4-S1(21):29-35.Breder VV, et al. Intermediate stage Hepatocellular carcinoma. BCLC B - official recommendations as a basic treatment strategy and a starting point of the assess of new approaches' effectiveness. Malignant Tumors. 2016;4-S1(21):29-35. (In Russ.).Kudo M, et al. Subclassification of BCLC B Stage Hepato-cellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria). Dig. Dis. 2015;6 (33):751-8.Kudo M, et al. Subclassification of BCLC B Stage Hepato-cellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria). Dig. Dis. 2015;6 (33):751-8.Kim JH, et al. New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization. Liver Int. 2017;12(37):1861-8.Kim JH, et al. New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization. Liver Int. 2017;12(37):1861-8.Raoul JL, et al. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat Rev. 2019;72:28-36.Raoul JL, et al. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat Rev. 2019;72:28-36.Yamada R, et al. Combined conventional transarterial chemoembolization with Mitomycin and percutaneous ablation for unresectable hepatocellular carcinoma. J Gastrointest Oncol. 2020;11 (2):298-303.Yamada R, et al. Combined conventional transarterial chemoembolization with Mitomycin and percutaneous ablation for unresectable hepatocellular carcinoma. J Gastrointest Oncol. 2020;11 (2):298-303.Lencioni R, et al. EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. JCO 42, LBA432-LBA432(2024). https://doi.org/10.1200/JCO.2024.42.3_suppl.LBA432.Lencioni R, et al. EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. JCO 42, LBA432-LBA432(2024). https://doi.org/10.1200/JCO.2024.42.3_suppl.LBA432.Ben Khaled N, Seidensticker M, Ricke J, et al. Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol. Future Oncol. 2022;18(12):1423-35. https://doi.org/10.2217/fon-2021-1261.Ben Khaled N, Seidensticker M, Ricke J, et al. Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol. Future Oncol. 2022;18(12):1423-35. https://doi.org/10.2217/fon-2021-1261.Виршке ЭР и др. Трансартериальная химиоэмболизация в комбинированном лечении больных с прогрессированием гепатоцеллюлярного рака в аллотрансплантате печени: клинический случай. Онкологический журнал: лучевая диагностика, лучевая терапия. 2023;6(3):81-9. https://doi.org/10.37174/2587-7593-2023-6-3-81-89. (In Russ.).Virshke ER, et al. Transarterial Chemoembolization in Therapy of Patients with Recurrence of Hepatocellular Cancer in a Liver Transplant: a Clinical Case. Journal of Ocology: Diagnostic Radiology and Radiotherapy. 2023;6(3):81-9. (In Russ.). https://doi.org/10.37174/2587-7593-2023-6-3-81-89. (In Russ.).Vogl J, et al. HCC: Transarterial Therapies - What the Interventional Radiologist Can. Offer Dig. Dis. Sci. 2019;64(4):959- 67.Vogl J, et al. HCC: Transarterial Therapies - What the Interventional Radiologist Can. Offer Dig. Dis. Sci. 2019;64(4):959- 67.Бредер ВВ и др. Трансартериальная химиоэмболизация в лечении больных локализованным гепатоцеллюлярным раком: отдаленные результаты и факторы прогноза. Вопросы онкологии. 2018;64 (6):793-8.Breder VV, et al. Transarterial chemoembolization in the treatment of patients with localized hepatocellular carcinoma: long-term results and prognosis factors. Problems in Oncology. 2018;64(6):793-8.Lucatelli P, Burrel M, Guiu B, de Rubeis G, van Delden O, Helmberger T. CIRSE Standards of Practice on Hepatic Transarterial Chemoembolisation. Cardiovasc Intervent Radiol. 2021;44(12):1851-67. https://doi.org/10.1007/s00270-021-02968-1.Lucatelli P, Burrel M, Guiu B, de Rubeis G, van Delden O, Helmberger T. CIRSE Standards of Practice on Hepatic Transarterial Chemoembolisation. Cardiovasc Intervent Radiol. 2021;44(12):1851-67. https://doi.org/10.1007/s00270-021-02968-1.Клинические рекомендации: Рак печени (гепатоцеллюлярный). Ред. совет: Абдурахманов ДТ и др. Москва, 2022.Clinical recommendations: Liver cancer (hepatocellular carcinoma). Ed. group: Abdurakhmanov DT, et al. Moscow, 2022. (In Russ.).Yamada R, Nakatsuka H, Nakamura K, et al. Nihon Igaku Hoshasen Gakkai Zasshi. 1979;39(5):540-3.Yamada R, Nakatsuka H, Nakamura K, et al. Nihon Igaku Hoshasen Gakkai Zasshi. 1979;39(5):540-3.Yamada R, Sato M, Kawabata M, et al. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology. 1983;148(2):397-401.Yamada R, Sato M, Kawabata M, et al. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology. 1983;148(2):397-401.Guan Y-S, He Q, Wang M-Q. Transcatheter arterial chemo-embolization: history for more than 30 years. ISRN Gastroenterol. 2012;2012:1-8.Guan Y-S, He Q, Wang M-Q. Transcatheter arterial chemo-embolization: history for more than 30 years. ISRN Gastroenterol. 2012;2012:1-8.Craig P, Young S, Golzarian J. Current Trends in the Treatment of Hepatocellular Carcinoma with Transarterial Embolization: Variability in Technical Aspects. Cardiovasc Intervent Radiol. 2019;2(9):1322-8.Craig P, Young S, Golzarian J. Current Trends in the Treatment of Hepatocellular Carcinoma with Transarterial Embolization: Variability in Technical Aspects. Cardiovasc Intervent Radiol. 2019;2(9):1322-8.Young S, Craig P, Golzarian J. Current trends in the treatment of hepatocellular carcinoma with transarterial embolization: a cross-sectional survey of techniques. Eur Radiol. 2019;29(6):3287-95.Young S, Craig P, Golzarian J. Current trends in the treatment of hepatocellular carcinoma with transarterial embolization: a cross-sectional survey of techniques. Eur Radiol. 2019;29(6):3287-95.Sahara S, Kawai N, Sato M, et al. Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2012;35(6):1363-71.Sahara S, Kawai N, Sato M, et al. Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2012;35(6):1363-71.Basile A, Carrafiello G, Ierardi AM, Tsetis D, Brountzos E. Quality-improvement guidelines for hepatic transarterial chemoembolization. Cardiovasc Intervent Radiol. 2012;35(4):765-74.Basile A, Carrafiello G, Ierardi AM, Tsetis D, Brountzos E. Quality-improvement guidelines for hepatic transarterial chemoembolization. Cardiovasc Intervent Radiol. 2012;35(4):765-74.Hong K, Khwaja A, Liapi E, Torbenson MS, Georgiades CS, Geschwind JF. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clincal cancer res. Official J Am Assoc. Cancer Res. 2006;12(8):2563-7.Hong K, Khwaja A, Liapi E, Torbenson MS, Georgiades CS, Geschwind JF. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clincal cancer res. Official J Am Assoc. Cancer Res. 2006;12(8):2563-7.Балахнин ПВ и др. Роль хирургических технологий в лечении вирус-ассоциированных опухолей на примере гепатоцеллюлярного рака. Практическая онкология. 19(4):348-77.Balakhnin PV, et al. The role of surgical technologies in the treatment of virus-associated tumors as hepatocellular carcinoma. Practical Oncology 19(4):348-77. (In Russ.).Iezzi R, Pompili M, Rinninella E, et al. TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib. Eur Radiol. 2019;29(3):1285-92.Iezzi R, Pompili M, Rinninella E, et al. TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib. Eur Radiol. 2019;29(3):1285-92.Gross A, Albrecht T. Transarterial Chemoembolisation (TACE) with Degradable Starch Microspheres (DSM) and Anthracycline in Patients with Locally Extensive Hepatocellular Carcinoma (HCC):Safety and Efficacy. Cardiovasc Intervent Radiol. 2020;43(3):402-10.Gross A, Albrecht T. Transarterial Chemoembolisation (TACE) with Degradable Starch Microspheres (DSM) and Anthracycline in Patients with Locally Extensive Hepatocellular Carcinoma (HCC): Safety and Efficacy. Cardiovasc Intervent Radiol. 2020;43(3):402-10.Schicho A, Pereira PL, Haimerl M, et al. Transarterial chemo-embolization (TACE) with degradable starch microspheres (DSM) in hepatocellular carcinoma (HCC):multicenter results on safety and efficacy. Oncotarget. 2017;8(42):72613-20.Schicho A, Pereira PL, Haimerl M, et al. Transarterial chemo-embolization (TACE) with degradable starch microspheres (DSM) in hepatocellular carcinoma (HCC):multicenter results on safety and efficacy. Oncotarget. 2017;8(42):72613-20.Irie T, Kuramochi M, Takahashi N. Dense accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective balloon-occluded transarterial chemoembolization: measurement of balloon-occluded arterial stump pressure. Cardiovasc Intervent Radiol. 2013;36(3):706-13.Irie T, Kuramochi M, Takahashi N. Dense accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective balloon-occluded transarterial chemoembolization: measurement of balloon-occluded arterial stump pressure. Cardiovasc Intervent Radiol. 2013;36(3):706-13.Mitchell DG, Bruix J, Sherman M, Sirlin CB. LI-RADS (Liver Imaging Reporting and Data System):Summary, discussion, and consensus of the LI-RADS Management Working Group and future directions. Hepatology. 2015;61(3):1056-65.Mitchell DG, Bruix J, Sherman M, Sirlin CB. LI-RADS (Liver Imaging Reporting and Data System): Summary, discussion, and consensus of the LI-RADS Management Working Group and future directions. Hepatology. 2015;61(3):1056-65.Di Tommaso L, Spadaccini M, Donadon M, et al. Role of liver biopsy in hepatocellular carcinoma. World J Gastroenterol. 2019;25(40):6041-52.Di Tommaso L, Spadaccini M, Donadon M, et al. Role of liver biopsy in hepatocellular carcinoma. World J Gastroenterol. 2019;25(40):6041-52.Lencioni R, Petruzzi P, Crocetti L. Chemoembolization of hepatocellular carcinoma. Semin Intervent Radiol. 2013;30(1):3-11.Lencioni R, Petruzzi P, Crocetti L. Chemoembolization of hepatocellular carcinoma. Semin Intervent Radiol. 2013;30(1):3-11.Shin SW. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. Korean J Radiol. 2009;10(5):425-34.Shin SW. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. Korean J Radiol. 2009;10(5):425-34.Schraml C, Kaufmann S, Rempp H, et al. Imaging of HCC-Current State of the Art. Diagnostics. 2015;5(4):513-45.Schraml C, Kaufmann S, Rempp H, et al. Imaging of HCC-Current State of the Art. Diagnostics. 2015;5(4):513-45.Miura JT, Rilling WS, White SB, et al. Safety and efficacy of transarterial chemoembolization in patients with transjugular intrahepatic portosystemic shunts. HPB. 2015;17(8):707-12.Miura JT, Rilling WS, White SB, et al. Safety and efficacy of transarterial chemoembolization in patients with transjugular intrahepatic portosystemic shunts. HPB. 2015;17(8):707-12.Natsuizaka M, et al. Clinical features of hepatocellular carci-noma with extrahepatic metastases. J Gastroenterol Hepatol. 2005;20(11):1781-7.Natsuizaka M, et al. Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol. 2005;20(11):1781-7.Stewart CJR, Coldewey J, Stewart IS. Comparison of fine needle aspiration cytology and needle core biopsy in the diagnosis of radiologically detected abdominal lesions. J Clin Pathol. 2002;55(2):93-7.Stewart CJR, Coldewey J, Stewart IS. Comparison of fine needle aspiration cytology and needle core biopsy in the diagnosis of radiologically detected abdominal lesions. J Clin Pathol. 2002;55(2):93-7.Sangiovanni A, et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut. 2010;59(5):638-44.Sangiovanni A, et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut. 2010;59(5):638-44.Benson AB, D'Angelica MI, Abrams T, et al. NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023. J Natl Compr Canc Netw. 2023;21(7):694-704. https://doi.org/10.6004/jnccn.2023.0035Benson AB, D'Angelica MI, Abrams T, et al. NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023. J Natl Compr Canc Netw. 2023;21(7):694-704. https://doi.org/10.6004/jnccn.2023.0035Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma [published correction appears in hepatology. 2023]. Hepatology. 2023;78(6):1922-65. https://doi.org/10.1097/HEP.0000000000000466Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma [published correction appears in hepatology. 2023]. Hepatology. 2023;78(6):1922-65. https://doi.org/10.1097/HEP.0000000000000466Lee MJ, Fanelli F, Haage P, et al Patient safety in interventional radiology: a CIRSE IR checklist. Cardiovasc Intervent Radiol. 2012 Apr;35(2):244-6. https://doi.org/10.1007/s00270-011-0289-5. Epub 2011. PMID: 22011783; PMCID: PMC3298647.Lee MJ, Fanelli F, Haage P, et al Patient safety in interventional radiology: a CIRSE IR checklist. Cardiovasc Intervent Radiol. 2012 Apr;35(2):244-6. https://doi.org/10.1007/s00270-011-0289-5. Epub 2011. PMID: 22011783; PMCID: PMC3298647.Бредер ВВ, Базин ИС, Балахнин ПВ, и др. Практические рекомендации по лекарственному лечению больных злокачественными опухолями печени и желчевыводящей системы. Практические рекомендации RUSSCO, часть 1. Злокачественные опухоли. 2023;13(3s2):494-538.Breder VV, Bazin IS, Balakhnin PV, et al. Practical recommendations for the treatment of patients with malignant tumors of the liver and biliary system. RUSSCO Practical recommendations, part 1. Malignant Tumors. 2023;13(3s2):494-538. (In Russ.).European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma [published correction appears in J Hepatol. 2019;70(4):817]. J Hepatol. 2018;69(1):182-236. Doi:10.1016/j.jhep.2018.03.019European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma [published correction appears in J Hepatol. 2019;70(4):817]. J Hepatol. 2018;69(1):182-236. Doi:10.1016/j.jhep.2018.03.019Aliberti C, Carandina R, Lonardi S, et al. Transarterial Chemo-embolization with Small Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: Experience from a Cohort of 421 Patients at an Italian Center. J Vasc Interv Radiol. 2017;28(11):1495-502.Aliberti C, Carandina R, Lonardi S, et al. Transarterial Chemo-embolization with Small Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: Experience from a Cohort of 421 Patients at an Italian Center. J Vasc Interv Radiol. 2017;28(11):1495-502.Aal AKA, Moawad S, Lune PV, et al. Survival Outcomes of Very Small Drug-Eluting Beads Used in Chemoembolization of Unresectable Hepatocellular Carcinoma. J Vasc Interv Radiol. 2019;30(9):1325-34.e1322.Aal AKA, Moawad S, Lune PV, et al. Survival Outcomes of Very Small Drug-Eluting Beads Used in Chemoembolization of Unresectable Hepatocellular Carcinoma. J Vasc Interv Radiol. 2019;30(9):1325-34.e1322.Patel IJ, Davidson JC, Nikolic B, et al. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol. 2012;23(6):727-36.Patel IJ, Davidson JC, Nikolic B, et al. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol. 2012;23(6):727-36.Hadi M, Walker C, Desborough M, et al. CIRSE Standards of Practice on Perioperative Anticoagulation Management During Interventional Radiology Procedures. Cardiovasc Intervent Radiol. 2021;44(4):523-36.Hadi M, Walker C, Desborough M, et al. CIRSE Standards of Practice on Perioperative Anticoagulation Management During Interventional Radiology Procedures. Cardiovasc Intervent Radiol. 2021;44(4):523-36.Tangkijvanich P, Anukulkarnkusol N, Suwangool P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol. 2000;31(4):302-8.Tangkijvanich P, Anukulkarnkusol N, Suwangool P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol. 2000;31(4):302-8.Arai T, Kobayashi A, Ohya A, et al. Assessment of treatment outcomes based on tumor marker trends in patients with re-current hepatocellular carcinoma undergoing trans-catheter arterial chemoembolization. Int J Clin Oncol. 2014;19(5):871- 9.Arai T, Kobayashi A, Ohya A, et al. Assessment of treatment outcomes based on tumor marker trends in patients with re-current hepatocellular carcinoma undergoing trans-catheter arterial chemoembolization. Int J Clin Oncol. 2014;19(5):871- 9.Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550-8.Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550-8.Rebonato A, Graziosi L, Maiettini D, et al. Inflammatory Markers as Prognostic Factors of Survival in Patients Affected by Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Gastroenterol Res Pract. 2017;2017:4164130-4164130.Rebonato A, Graziosi L, Maiettini D, et al. Inflammatory Markers as Prognostic Factors of Survival in Patients Affected by Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Gastroenterol Res Pract. 2017;2017:4164130-4164130.Toyoda H, Kumada T, Sone Y. Impact of a Unified CT Angiography System on Outcome of Patients with Hepatocellular Carcinoma. Am J Roentgenol. 2009;192(3):766-74.Toyoda H, Kumada T, Sone Y. Impact of a Unified CT Angiography System on Outcome of Patients with Hepatocellular Carcinoma. Am J Roentgenol. 2009;192(3):766-74.De Baere T, Dufaux J, Roche A, et al. Circulatory alterations induced by intra-arterial injection of iodized oil and emulsions of iodized oil and doxorubicin: experimental study. Radiology. 1995;194(1):165-70.De Baere T, Dufaux J, Roche A, et al. Circulatory alterations induced by intra-arterial injection of iodized oil and emulsions of iodized oil and doxorubicin: experimental study. Radiology. 1995;194(1):165-70.Ogasawara S, Chiba T, Ooka Y, et al. A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization. Hepatology. 2018;67(2):575-85.Ogasawara S, Chiba T, Ooka Y, et al. A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization. Hepatology. 2018;67(2):575-85.Iezzi R, Kovacs A, Prenen H, Chevallier P, Pereira PL. Transarterial chemoembolisation of colorectal liver metastases with irinotecan-loaded beads: What every interventional radiologist should know. Eur J Radiol Open. 2020;7:100236.Iezzi R, Kovacs A, Prenen H, Chevallier P, Pereira PL. Transarterial chemoembolisation of colorectal liver metastases with irinotecan-loaded beads: What every interventional radiologist should know. Eur J Radiol Open. 2020;7:100236.Wang TC, Zhang ZS, Xiao YD. Determination of Risk Factors for Pain After Transarterial Chemoembolization with Drug-Eluting Beads for Hepatocellular Carcinoma. J Pain Res. 2020;13:649-56.Wang TC, Zhang ZS, Xiao YD. Determination of Risk Fac¬tors for Pain After Transarterial Chemoembolization with Drug-Eluting Beads for Hepatocellular Carcinoma. J Pain Res. 2020;13:649-56.Benzakoun J, Ronot M, Lagadec M, et al. Risks factors for severe pain after selective liver transarterial chemoembolization. Liver Int. 2017;37(4):583-91.Benzakoun J, Ronot M, Lagadec M, et al. Risks factors for se-vere pain after selective liver transarterial chemoembolization. Liver Int. 2017;37(4):583-91.Интервенционная радиология в онкологии. Национальное руководство в 3-х томах. Ред. Долгушин БИ. Москва: Видар-М, 2022. 783 с.Interventional radiology in Oncology. National Guidelines in 3 volumes. Ed. by Dolgushin BI. Moscow: 2022. - 783 p. (In Russ.).Chehab MA, Thakor AS, Tulin-Silver S, et al. Adult and Pediatric Antibiotic Prophylaxis during Vascular and IR Procedures: A Society of Interventional Radiology Practice Parameter Update Endorsed by the Cardiovascular and Interventional Radiological Society of Europe and the Canadian Association for Interventional Radiology. J Vasc Interv Radiol. 2018;29(11):1483-501.e1482.Chehab MA, Thakor AS, Tulin-Silver S, et al. Adult and Pediatric Antibiotic Prophylaxis during Vascular and IR Procedures: A Society of Interventional Radiology Practice Parameter Update Endorsed by the Cardiovascular and Interventional Radiological Society of Europe and the Canadian Association for Interventional Radiology. J Vasc Interv Radiol. 2018;29(11):1483-501.e1482.Lucatelli P, Corona M, Argiro R, et al. Impact of 3D Rotational Angiography on Liver Embolization Procedures: Review of Technique and Applications. Cardiovasc Intervent Radiol. 2015;38(3):523-35.Lucatelli P, Corona M, Argiro R, et al. Impact of 3D Rotation-al Angiography on Liver Embolization Procedures: Review of Technique and Applications. Cardiovasc Intervent Radiol. 2015;38(3):523-35.Pung L, Ahmad M, Mueller K, et al. The Role of Cone-Beam CT in Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. J Vasc Interv Radiol. 2017;28(3):334-41.Pung L, Ahmad M, Mueller K, et al. The Role of Cone-Beam CT in Transcatheter Arterial Chemoembolization for Hepato-cellular Carcinoma: A Systematic Review and Meta-Analysis. J Vasc Interv Radiol. 2017;28(3):334-41.Lucatelli P, De Rubeis G, Ginnani Corradini L, et al. Intraprocedural dual phase cone beam computed tomography has a better diagnostic accuracy over pre-procedural MRI and MDCT in detection and characterization of HCC in cirrhotic patients undergoing TACE procedure. Eur J Radiol. 2020;124:108806.Lucatelli P, De Rubeis G, Ginnani Corradini L, et al. Intraprocedural dual phase cone beam computed tomography has a better diagnostic accuracy over pre-procedural MRI and MDCT in detection and characterization of HCC in cirrhotic patients undergoing TACE procedure. Eur J Radiol. 2020;124:108806.Lucatelli P, Argiro R, Bascetta S, et al. Single injection dual phase CBCT technique ameliorates results of trans-arterial chemoembolization for hepatocellular cancer. Transl Gastroenterol Hepatol. 2017;2:83.Lucatelli P, Argiro R, Bascetta S, et al. Single injection dual phase CBCT technique ameliorates results of trans-arterial chemoembolization for hepatocellular cancer. Transl Gastroenterol Hepatol. 2017;2:83.Durack JC, Brown KT, Avignon G, et al. Assessment of automated cone-beam CT vessel identification software during transarterial hepatic embolisation: radiation dose, contrast medium volume, processing time, and operator perspectives compared to digital subtraction angiography. Clin Radiol. 2018;73(12):1057.e1-1057.e6. https://doi.org/10.1016/j.crad.2018.08.005. Epub 2018.Durack JC, Brown KT, Avignon G, et al. Assessment of automated cone-beam CT vessel identification software during transarterial hepatic embolisation: radiation dose, contrast medium volume, processing time, and operator perspectives compared to digital subtraction angiography. Clin Radiol. 2018;73(12):1057.e1-1057.e6. https://doi.org/10.1016/j.crad.2018.08.005. Epub 2018.Wang X, Yarmohammadi H, Cao G, et al. Dual phase cone-beam computed tomography in detecting <3 cm hepato-cellular carcinomas during transarterial chemoembolization. J Cancer Res Ther. 2017;13(1):38-43. https://doi.org/10.4103/0973-1482.206242.Wang X, Yarmohammadi H, Cao G, et al. Dual phase cone-beam computed tomography in detecting <3 cm hepato-cellular carcinomas during transarterial chemoembolization. J Cancer Res Ther. 2017;13(1):38-43. https://doi.org/10.4103/0973-1482.206242.Kim HC. Role of C-arm cone-beam CT in chemoembolization for hepatocellular carcinoma. Korean J Radiol. 2015;16(1):114-24. https://doi.org/10.3348/kjr.2015.16.1.114. Epub 2015.Kim HC. Role of C-arm cone-beam CT in chemoembolization for hepatocellular carcinoma. Korean J Radiol. 2015;16(1):114-24. https://doi.org/10.3348/kjr.2015.16.1.114. Epub 2015.Tacher V, Radaelli A, Lin M, Geschwind JF. How I do it: Cone-beam CT during transarterial chemoembolization for liver cancer. Radiology. 2015;274(2):320-34. https://doi.org/10.1148/radiol.14131925.Tacher V, Radaelli A, Lin M, Geschwind JF. How I do it: Cone-beam CT during transarterial chemoembolization for liver cancer. Radiology. 2015;274(2):320-34. https://doi.org/10.1148/radiol.14131925.Балахнин ПВ, Беляев АМ, Багненко СС и др. Технологии плоскодетекторной компьютерной томографии в интервенционной онкологии: Диагностика, стадирование и лечение гепатоцеллюлярного рака. Медицина высоких технологий. 2023;1(1):6-25.Balakhnin PV, Belyaev AM, Bagnenko SS, et al. Flat-detector computed tomography technologies in interventional oncology: Diagnosis, staging and treatment of hepatocellular carcinoma. High-tech Medicine. 2023;1(1):6-25. (In Russ.).Tanaka T, Arai Y, Inaba Y, et al. Current role of hybrid CT/angiography system compared with C-arm cone beam CT for interventional oncology. Br J Radiol. 2014;87(1041):20140126.Tanaka T, Arai Y, Inaba Y, et al. Current role of hybrid CT/angiography system compared with C-arm cone beam CT for interventional oncology. Br J Radiol. 2014;87(1041):20140126.

The authors declare that there are no conflicts of interest present.